MA56827A1 - Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine - Google Patents

Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine

Info

Publication number
MA56827A1
MA56827A1 MA56827A MA56827A MA56827A1 MA 56827 A1 MA56827 A1 MA 56827A1 MA 56827 A MA56827 A MA 56827A MA 56827 A MA56827 A MA 56827A MA 56827 A1 MA56827 A1 MA 56827A1
Authority
MA
Morocco
Prior art keywords
lurbinectedin
methods
small cell
cell lung
relates
Prior art date
Application number
MA56827A
Other languages
English (en)
Other versions
MA56827B2 (fr
Inventor
Pilar Calvo
Carmen Kahatt
José María Fernandez
Maria Tobio
Salvador Fudio
Arturo Soto
Pilar Lardelli
Cristian Fernandez
Alba Maria Del Mar Zarzuelo
Noain María De La Concepción Polanco
López Sonia Manzanaro
Honorio Velasco
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Priority claimed from PCT/EP2020/065093 external-priority patent/WO2021098992A1/fr
Publication of MA56827A1 publication Critical patent/MA56827A1/fr
Publication of MA56827B2 publication Critical patent/MA56827B2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des procédés de traitement de patients atteints de cancer du poumon à petites cellules par administration intraveineuse de quantités thérapeutiques de lurbinectédine par perfusion intraveineuse. L'invention concerne également des procédés de traitement du cancer par administration de lurbinectédine en combinaison avec d'autres médicaments anticancéreux, en particulier des inhibiteurs de la topoisomérase. L'invention concerne en outre l'administration de lurbinectédine en combinaison avec des agents antiémétique pour lutter efficacement contre les symptômes liés à la nausée et aux vomissements, des doses de lurbinectedine réduites pour obtenir une administration plus sûre et une augmentation du nombre de cycles de traitement. L'invention concerne également des formulations lyophilisées stables de lurbinectédine.
MA56827A 2019-11-21 2020-05-29 Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine MA56827B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19383025 2019-11-21
PCT/EP2020/065093 WO2021098992A1 (fr) 2019-11-21 2020-05-29 Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine

Publications (2)

Publication Number Publication Date
MA56827A1 true MA56827A1 (fr) 2023-01-31
MA56827B2 MA56827B2 (fr) 2023-09-27

Family

ID=68808231

Family Applications (1)

Application Number Title Priority Date Filing Date
MA56827A MA56827B2 (fr) 2019-11-21 2020-05-29 Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine

Country Status (4)

Country Link
US (4) US20230014782A1 (fr)
MA (1) MA56827B2 (fr)
TW (1) TW202132318A (fr)
WO (1) WO2021099635A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3229559A1 (fr) * 2021-08-31 2023-03-09 Srinivasa Chary CHINTALAPATI Nouveau polymorphe cristallin de lurbinectedine et methode amelioree pour la preparation de lurbinectedine
WO2023084329A1 (fr) * 2021-11-15 2023-05-19 Rk Pharma Inc. Procédé amélioré pour la préparation de lurbinectédine et de ses morphes
CN115246846A (zh) * 2021-11-19 2022-10-28 江苏慧聚药业股份有限公司 卢比替定新晶型及其制备
CN115304619A (zh) * 2022-04-08 2022-11-08 上海皓元医药股份有限公司 一种卢比替定的晶型及其制备方法
CN114940682A (zh) * 2022-05-18 2022-08-26 博瑞制药(苏州)有限公司 芦比替定的晶型及其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119243D0 (en) 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
JP6037337B2 (ja) * 2010-05-25 2016-12-07 ファルマ、マール、ソシエダード、アノニマＰｈａｒｍａ Ｍｒｓ，Ｓ．Ａ． エクチナサイジン化合物の製造のための合成方法
EP2786755A3 (fr) 2010-11-12 2014-10-29 Pharma Mar S.A. Thérapie de combinaison avec un alcaloïde anti-tumoral

Also Published As

Publication number Publication date
WO2021099635A1 (fr) 2021-05-27
MA56827B2 (fr) 2023-09-27
TW202132318A (zh) 2021-09-01
US20230399345A1 (en) 2023-12-14
US20230014782A1 (en) 2023-01-19
US20230399344A1 (en) 2023-12-14
US20230416276A1 (en) 2023-12-28

Similar Documents

Publication Publication Date Title
MA56827A1 (fr) Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine
RU2015100529A (ru) Способы лечения рака поджелудочной железы с применением комбинированной терапии, включающей липосомный иринотекан
EA200501203A1 (ru) Жидкие фармацевтические композиции палоносетрона
NZ621433A (en) Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
EA201490279A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
DK1750716T3 (da) Behandling af T-celle-lymfom under anvendelse af 10-propargyl-10-deazaaminopterin
EA026870B1 (ru) Комбинация и фармацевтическая композиция для лечения опухолей
WO2014160216A3 (fr) Agents anticancéreux à double ciblage
RU2013123646A (ru) Комбинированная композиция
NZ630314A (en) Combination therapy for hematological malignancies
BARBIERI et al. Current alternatives in the prevention and treatment of xerostomia in cancer therapy
AR110800A1 (es) MÉTODOS PARA AUMENTAR EN PLASMA SANGUÍNEO LA 2’-DESOXIURIDINA (dUrd) Y LA INHIBICIÓN DE LA TIMIDILATO SINTASA
CO2022008437A2 (es) Métodos de tratamiento del cáncer de pulmón de cé-lulas pequeñas con formulaciones de lurbinectedina
MX2022000430A (es) Administracion de agonista de sting e inhibidores de puntos de control.
Chitasombat et al. Deferiprone as adjunctive treatment for patients with invasive mucormycosis: A retrospective case series
ES2777250T3 (es) Método para el tratamiento del cáncer y las enfermedades concomitantes del cáncer
KR20130118981A (ko) 다형 교모세포종의 치료를 위한 마시텐탄 포함 조합물
UA93365C2 (ru) Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты)
RU2015111907A (ru) Способ лечения хронического воспаления тканей пародонта и слизистой оболочки с элементами гиперкератоза у лиц молодого возраста
Dinota et al. Biweekly administration of gemcitabine and vinorelbine as first line therapy in elderly advanced breast cancer
US10441564B2 (en) Fructose analogs and their combinations as anti-cancer agents
EA202192328A1 (ru) Комбинация назальной доставки генов и пероральной доставки коричной кислоты, олеамида или гемфиброзила для лечения лизосомных болезней накопления
RU2018144248A (ru) Схемы дозирования вортиоксетина для быстрого появления антидепрессивного эффекта
HRP20210894T1 (hr) Poboljšana kisela alfa-glukozidaza za liječenje pompeove bolesti
RU2696287C2 (ru) Способ лечения кастрационно-устойчивого рака простаты